News | May 30, 2025
Alkem reports 7.1% YoY revenue growth in Q4 FY25
Annual EBITDA margin expands by 170 basis points
Annual EBITDA margin expands by 170 basis points
The decision to withdraw the BLA is based on topline overall survival (OS) results from the confirmatory HERTHENA-Lung02 Phase 3 trial where OS did not meet statistical significance
YESINTEK is indicated for the treatment of adults and children from the age of 6 years and olde
Orion will be the exclusive partner for the distribution, marketing, and sales of Shilpa's Recombinant Human Albumin in Europe
IICP is a registered charitable society working in the disability sector since 1974
She has held senior positions at Coca-Cola in China and PepsiCo in India
Net Profit increased by 15% to Rs. 146 crores in Q4 FY25 and 19% to Rs. 660 crores in FY25
CuraTeQ Biologics receives approval for biosimilar Zefylti from UK’s MHRA
This significant milestone enhances our global regulatory standing
The positive opinions are based on applications submitted by Biosimilar Collaborations Ireland Limited
Subscribe To Our Newsletter & Stay Updated
